The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Exploring durvalumab + bevacizumab + TACE in hepatocellular carcinoma: EMERALD-1 insights
Mark Yarchoan, MD, from Johns Hopkins University in Baltimore, MD, discusses the significance of the EMERALD-1 (NCT03778957) trial. The Phase III study explores the combination of durvalumab and bevacizumab with transarterial chemoembolization (TACE) in the intermediate setting for unresectable hepatocellular carcinoma. While it demonstrates safety and a progression-free survival (PFS) benefit, Dr Yarchoan emphasizes the need for longer follow-up to understand the durability of the benefits. He points out the absence of a TACE-free arm, raising the question of whether systemic therapy, as seen in this study, might replace TACE. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
